Artificial extracellular matrix composed of collagen i and highly sulfated hyaluronan interferes with TGFβ1 signaling and prevents TGFβ1-induced myofibroblast differentiation

Acta Biomaterialia

Volumn 9, Issue 8, 2013, Pages 7775-7786

  Van Der Smissen, Anja ^a,d   Samsonov, Sergey ^b,d   Hintze, Vera ^b,d   Scharnweber, Dieter ^b,d   Moeller, Stephanie ^c,d   Schnabelrauch, Matthias ^c,d   Pisabarro, M Teresa ^b,d   Anderegg, Ulf ^a,d  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c BIOMATERIALS DEPARTMENT   (Germany)

^d Collaborative Research Center ^*  (Germany)

Author keywords

Collagen I; Myofibroblast; Sulfated hyaluronan; Transforming growth factor b1; Wound healing

Indexed keywords

BIOACTIVITY; BIOSYNTHESIS; CELL CULTURE; COLLAGEN; HYALURONIC ACID; MATRIX ALGEBRA; SIGNAL TRANSDUCTION; SULFUR COMPOUNDS; TISSUE;

COLLAGEN I; DERMAL FIBROBLASTS; EXTRACELLULAR MATRICES; HYALURONAN; MYOFIBROBLASTS; SMOOTH MUSCLE ACTINS; SULFATED HYALURONAN; TRANSFORMING GROWTH FACTOR B1; TRANSFORMING GROWTH FACTORS; WOUND HEALING;

FIBROBLASTS;

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FIBRONECTIN; HYALURONIC ACID; TRANSFORMING GROWTH FACTOR BETA1; BIOMIMETIC MATERIAL; SULFATE;

ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; DOWNSTREAM PROCESSING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MYOFIBROBLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CHEMISTRY; CYTOLOGY; MATERIALS TESTING; METABOLISM; PHYSIOLOGY; SURFACE PROPERTY;

BIOMIMETIC MATERIALS; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; HUMANS; HYALURONIC ACID; MATERIALS TESTING; MYOFIBROBLASTS; SIGNAL TRANSDUCTION; SULFATES; SURFACE PROPERTIES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84891693365     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.04.023     Document Type: Article

References (71)

1. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol 2007;127:1018-29.
2. Hackam DJ, Ford HR. Cellular, biochemical, and clinical aspects of wound healing. Surg Infect (Larchmt) 2002;3(Suppl. 1):S23-35.
3. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-70.
4. Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 2007;127:998-1008.
5. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007;127:526-37.
6. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63.
7. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-3.
8. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990;63:21-9.
9. Hinck AP, Archer SJ, Qian SW, Roberts AB, Sporn MB, Weatherbee JA, et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 1996;35:8517-34.
10. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217-24.
11. Miyazono K, Heldin CH. Latent forms of TGF-beta: molecular structure and mechanisms of activation. Ciba Found Symp 1991;157:81-9.
12. Klass BR, Grobbelaar AO, Rolfe KJ. Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad Med J 2009;85:9-14.
13. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
14. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007;179:1311-23.
15. Kunze R, Rosler M, Moller S, Schnabelrauch M, Riemer T, Hempel U, et al. Sulfated hyaluronan derivatives reduce the proliferation rate of primary rat calvarial osteoblasts. Glycoconj J 2010;27:151-8.
16. Schiller J, Becher J, Moller S, Nimptsch K, Riemer T, Schnabelrauch M. Synthesis and characterization of chemically modified hyaluronan and chondroitin sulfate. Mini-Rev Org Chem 2010;7:290-9.
17. Clark RA. Cutaneous tissue repair: basic biologic considerations. I. J Am Acad Dermatol 1985;13:701-25.
18. Hintze V, Moeller S, Schnabelrauch M, Bierbaum S, Viola M, Worch H, et al. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009;10:3290-7.
19. Lavenus S, Pilet P, Guicheux J, Weiss P, Louarn G, Layrolle P. Behaviour of mesenchymal stem cells, fibroblasts and osteoblasts on smooth surfaces. Acta Biomater 2011;7:1525-34.
20. Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Eng 2006;8:181-231.
21. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: hostassociated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22.
22. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008;72:455-82.
23. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009;326:1216-9.
24. Salek-Ardakani S, Arrand JR, Shaw D, Mackett M. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood 2000;96:1879-88.
25. Gama CI, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, et al. Sulfation patterns of glycosaminoglycans encode molecular recognition and activity. Nat Chem Biol 2006;2:467-73.
26. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. The heparanome - the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol 2007;129:290-307.
27. Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, et al. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J Immunol 2010;184:2677-85.
28. Coombe DR. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 2008;86:598-607.
29. van der Smissen A, Hintze V, Scharnweber D, Moeller S, Schnabelrauch M, Majok A, et al. Growth promoting substrates for human dermal fibroblasts provided by artificial extracellular matrices composed of collagen I and sulfated glycosaminoglycans. Biomaterials 2011;32:8938-46.
30. Moeller S, Schmidtke M, Weiss D, Schiller J, Pawlik K, Wutzler P, et al. Synthesis and antiherpetic activity of carboxymethylated and sulfated hyaluronan derivatives. Carbohydr Polym 2012;90:608-15.
31. Hempel U, Hintze V, Moller S, Schnabelrauch M, Scharnweber D, Dieter P. Artificial extracellular matrices composed of collagen I and sulfated hyaluronan with adsorbed transforming growth factor beta1 promote collagen synthesis of human mesenchymal stromal cells. Acta Biomater 2012;8:659-66.
32. Saalbach A, Klein C, Schirmer C, Briest W, Anderegg U, Simon JC. Dermal fibroblasts promote the migration of dendritic cells. J Invest Dermatol 2010;130:444-54.
33. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res 1993;21:1498.
34. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-84.
35. Kadirvelraj R, Gonzalez-Outeirino J, Foley BL, Beckham ML, Jennings HJ, Foote S, et al. Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus Streptococcus pneumoniae. Proc Natl Acad Sci USA 2006;103:8149-54.
36. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 1996;10:293-304.
37. Ester M, Kriegel HP, Sander J, Xu X. A density-based algorithm for discovering clusters in large spatial databases with noise. In: Proceedings of 2nd International Conference on Knowledge Discovery and Data Mining (KDD-96), 1996.
38. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factorbeta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-11.
39. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999;250:273-83.
40. Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000;257:180-9.
41. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol 1992;152:430-40.
42. Hintze V, Miron A, Moeller S, Schnabelrauch M, Wiesmann HP, Worch H, et al. Sulfated hyaluronan and chondroitin sulfate derivatives interact differently with human transforming growth factor-beta1 (TGF-beta1). Acta Biomater 2012;8:2144-52.
43. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
44. Sarrazy V, Billet F, Micallef L, Coulomb B, Desmouliere A. Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen 2011;19(Suppl. 1):s10-5.
45. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66.
46. Schurch W, Seemayer TA, Hinz B, Gabbiani G. The Myofibroblast. In: Mills SE, editor. Histology for Pathologists, Philadelphia: Lippincott-Williams & Wilkins Publishers; 2007. p. 123-164.
47. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011;121:985-97.
48. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983;258:7155-60.
49. Nolte SV, Xu W, Rennekampff HO, Rodemann HP. Diversity of fibroblasts - a review on implications for skin tissue engineering. Cells Tissues Organs 2008;187:165-76.
50. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
51. Gu L, Zhu YJ, Yang X, Guo ZJ, Xu WB, Tian XL. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin 2007;28:382-91.
52. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 2008;283:10226-31.
53. Kim SI, Kwak JH, Zachariah M, He Y, Wang L, Choi ME. TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am J Physiol Renal Physiol 2007;292:F1471-8.
54. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha(V)beta(3) engagement and PI3K/pAkt/NFkappaB signaling. Hepatology 2012;55:594-608.
55. Hauburger A, von ES, Schwaerzer GK, Buttstedt A, Zebisch M, Schraml M, et al. The pro-form of BMP-2 interferes with BMP-2 signalling by competing with BMP-2 for IA receptor binding. FEBS J 2009;276:6386-98.
56. Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 2004;18:469-79.
57. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T, et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004;91:915-25.
58. Choi J, Park EJ, Shin HS, Shin IS, Ra JC, Koh KS. In vivo differentiation of undifferentiated human adipose tissue-derived mesenchymal stem cells in critical-sized calvarial bone defects. Ann Plast Surg 2012.
59. Blobe GC, Liu X, Fang SJ, How T, Lodish HF. A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 2001;276:39608-17.
60. Chen CL, Huang SS, Huang JS. Cellular heparan sulfate negatively modulates transforming growth factor-beta1 (TGF-beta1) responsiveness in epithelial cells. J Biol Chem 2006;281:11506-14.
61. Rogers CJ, Clark PM, Tully SE, Abrol R, Garcia KC, Goddard WA, et al. Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches. Proc Natl Acad Sci USA 2011;108:9747-52.
62. Rusnati M, Coltrini D, Caccia P, Dell'Era P, Zoppetti G, Oreste P, et al. Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 1994;203:450-8.
63. Gallagher JT, Turnbull JE. Heparan sulphate in the binding and activation of basic fibroblast growth factor. Glycobiology 1992;2:523-8.
64. Nissen NN, Shankar R, Gamelli RL, Singh A, DiPietro LA. Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J 1999;338(3):637-42.
65. Richardson TP, Trinkaus-Randall V, Nugent MA. Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate. J Biol Chem 1999;274:13534-40.
66. Radek KA, Taylor KR, Gallo RL. FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation. Wound Repair Regen 2009;17:118-26.
67. Chen Y, Shi-Wen X, van BJ, Kennedy L, McLeod M, Renzoni EA, et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/ activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167:1699-711.
68. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BB. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol 1989;109:441-8.
69. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol 1994;159:51-9.
70. Logeart-Avramoglou D, Huynh R, Chaubet F, Sedel L, Meunier A. Interaction of specifically chemically modified dextrans with transforming growth factor beta1: potentiation of its biological activity. Biochem Pharmacol 2002;63:129-37.
71. Radaev S, Zou Z, Huang T, Lafer EM, Hinck AP, Sun PD. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 2010;285:14806-14.